We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Material Developed for Vascular Graft

By HospiMedica staff writers
Posted on 20 Jul 2006
A new material, intended for use in vascular grafts, could help patients with damaged arteries regenerate new ones when undergoing coronary artery graft surgery.

The new material, developed by scientists at Virginia Commonwealth University (VCU, Richmond, USA), is a blend of polydioxanone (PDO), a synthetic biodegradable polymer that has been used in suture materials for years, and elastin fibers, used to enhance elasticity and bioactivity of the graft. More...
Elastin, a natural polymer, is also a major component of the arterial wall and is critical to the graft in providing a base for the cells to recognize and interact with the body. Using a technique known as electro-spinning, the researchers were able to manipulate the PDO-elastin composite into a conduit, or hose, for use as a small diameter vascular graft.

The fibers of the new material are fewer than 500 nm in diameter, compared with the average hair shaft, which is 80,000-100,000 nm. The PDO-elastin blend undergoes slow degradation and causes few adverse reactions compared with previous materials used for the same purpose. The composition of the new material reinforces the graft's mechanical strength, which is critical in order to resist the hydraulic forces generated by blood pressure while the regeneration process is taking place. The purpose of the new material would be to help a patient to generate a new artery, and if it works as designed, the researchers hope that at six months post-surgery there would be no more synthetic structure left.

"Regeneration needs to be timed just right, and the cells' regrowth needs to be strong enough so that the patient's own artery can take over for the synthetic material and promote regeneration,” said lead author Gary Bowlin, Ph.D., the Harris professor of biomedical engineering at the VCU School of Engineering. "Additionally, the synthetic material must degrade, because any foreign material in the body for an extended time is susceptible to inflammatory response or even severe infection such as staphylococcus.”



Related Links:
Virginia Commonwealth University

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.